NO20084909L - Nye krystallformer - Google Patents

Nye krystallformer

Info

Publication number
NO20084909L
NO20084909L NO20084909A NO20084909A NO20084909L NO 20084909 L NO20084909 L NO 20084909L NO 20084909 A NO20084909 A NO 20084909A NO 20084909 A NO20084909 A NO 20084909A NO 20084909 L NO20084909 L NO 20084909L
Authority
NO
Norway
Prior art keywords
new crystal
crystal shapes
shapes
new
difluorochromoman
Prior art date
Application number
NO20084909A
Other languages
English (en)
Norwegian (no)
Inventor
Alexander Beliaev
David Learmonth
Valeriya Smolenskaya
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of NO20084909L publication Critical patent/NO20084909L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20084909A 2006-05-31 2008-11-24 Nye krystallformer NO20084909L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0610804.7A GB0610804D0 (en) 2006-05-31 2006-05-31 New crystal forms
GBGB0706647.5A GB0706647D0 (en) 2006-05-31 2007-04-04 New crystal forms
PCT/PT2007/000023 WO2007139413A2 (en) 2006-05-31 2007-05-31 Polymorphs of (r) -5- (2-aminoethyl) -1- (6, 8-difluorochroman-3-yl) -1,3- dihydroimidazole-thione hydrochloride

Publications (1)

Publication Number Publication Date
NO20084909L true NO20084909L (no) 2008-12-23

Family

ID=36694737

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084909A NO20084909L (no) 2006-05-31 2008-11-24 Nye krystallformer

Country Status (16)

Country Link
US (1) US20100113550A1 (zh)
EP (1) EP2027118A2 (zh)
JP (1) JP2009538904A (zh)
KR (1) KR20090014225A (zh)
CN (1) CN101484451A (zh)
AR (1) AR061418A1 (zh)
AU (1) AU2007268380A1 (zh)
BR (1) BRPI0711508A2 (zh)
CA (1) CA2653956A1 (zh)
GB (2) GB0610804D0 (zh)
IL (1) IL195529A0 (zh)
MX (1) MX2008015044A (zh)
NO (1) NO20084909L (zh)
RU (1) RU2008151891A (zh)
WO (1) WO2007139413A2 (zh)
ZA (1) ZA200810190B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053997A1 (en) * 2007-12-05 2011-03-03 Alexander Beliaev Salts and Crystal Forms
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
LT2919780T (lt) * 2012-11-14 2018-11-12 Bial - Portela & Ca., S.A. 1,3-dihidroimidazol-2-tiono dariniai, skirti panaudoti gydant plautinę arterinę hipertenziją ir plaučių pažeidimą

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991106A (en) * 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4032617A (en) * 1975-12-03 1977-06-28 Olin Corporation Bis(3,5-difluorosalicylaldehyde)ethylenediimine-Co+2 compound and use
US4395417A (en) * 1980-04-22 1983-07-26 Research Corporation Antihyperlipidemic compositions
USRE32868E (en) * 1980-04-22 1989-02-14 Research Corporation Antihyperlipidemic compositions
GB8401288D0 (en) * 1984-01-18 1984-02-22 Pfizer Ltd Therapeutic agents
WO1989005643A1 (en) * 1987-12-18 1989-06-29 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
CA2153498A1 (en) * 1993-11-10 1995-05-18 Hidetsura Cho Chroman derivative and medicinal use thereof
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US20070060595A1 (en) * 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
EP1574499A1 (en) * 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
US20050245489A1 (en) * 2004-05-03 2005-11-03 Pinney Kevin G Chromene-containing compounds with anti-tubulin and vascular targeting activity
US7456214B2 (en) * 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
US7528267B2 (en) * 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes

Also Published As

Publication number Publication date
AU2007268380A1 (en) 2007-12-06
GB0610804D0 (en) 2006-07-12
US20100113550A1 (en) 2010-05-06
WO2007139413A3 (en) 2008-04-03
MX2008015044A (es) 2008-12-10
CN101484451A (zh) 2009-07-15
IL195529A0 (en) 2009-09-01
AR061418A1 (es) 2008-08-27
JP2009538904A (ja) 2009-11-12
KR20090014225A (ko) 2009-02-06
EP2027118A2 (en) 2009-02-25
BRPI0711508A2 (pt) 2011-11-01
GB0706647D0 (en) 2007-05-16
RU2008151891A (ru) 2010-07-10
WO2007139413A2 (en) 2007-12-06
ZA200810190B (en) 2009-08-26
CA2653956A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
JO2630B1 (en) Organic compounds
EP1954683A4 (en) 2- (PHENYL OR HETEROCYCLIC) -1H-PHENANTRHO (9,10-D) IMIDAZOLES AS INHIBITORS OF MPGES-1
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
MX2010003760A (es) Derivados de n-(pirazol-3-il)-benzamida como activadores de glucocinasa.
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
CY1112483T1 (el) Αγωνιστες gpcr πιπεριδινης
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
NO20080010L (no) GPCR-agonister
TW200716512A (en) Processes for preparing cinacalcet hydrochloride crystal form I
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
IL180147A0 (en) N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
DE602007010303D1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
HK1158192A1 (en) Piperidine gpcr agonists
HK1157329A1 (en) Piperidinyl gpcr agonists
CY1112919T1 (el) Παραγωγα β-αμινοξεων για τη θεραπευτικη αντιμετωπιση του διαβητη
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
MY150046A (en) Benzothiazoles as ghrelin receptor modulators
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
IN2012DN03844A (zh)
NO20084909L (no) Nye krystallformer
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application